TransMedics Group’s (TMDX) “Hold” Rating Reaffirmed at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX)‘s stock had its “hold” rating reissued by investment analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

A number of other equities analysts have also issued reports on TMDX. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Robert W. Baird lowered their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. JPMorgan Chase & Co. dropped their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. Finally, Piper Sandler decreased their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $126.80.

TransMedics Group Stock Performance

Shares of TMDX opened at $65.71 on Wednesday. The business has a 50-day simple moving average of $98.83 and a two-hundred day simple moving average of $132.44. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of 69.90 and a beta of 2.06. TransMedics Group has a 52 week low of $65.26 and a 52 week high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s revenue was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.12) earnings per share. On average, analysts expect that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,042 shares of company stock valued at $3,563,985 in the last quarter. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in the stock. International Assets Investment Management LLC purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at about $47,000. USA Financial Formulas purchased a new stake in TransMedics Group during the 3rd quarter worth $55,000. Quarry LP raised its position in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after purchasing an additional 312 shares in the last quarter. National Bank of Canada FI grew its stake in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares in the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.